11 Results for "

CDK4/Cyclin D1 kinase

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "CDK4/Cyclin D1 kinase" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-10424
CAS No.: 802539-81-7
Purity:  99.90%
Synonyms: PHA-848125
Target:  

CDK Autophagy

Research Areas:  

Cancer

Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16559
CAS No.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18981
CAS No.: 5928-25-6
Synonyms: (+)-Decursin
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .
loading...
    loading...
Cat. No.: HY-P1109
CAS No.: 189064-08-2
Target:  

CDK

Research Areas:  

Cancer

[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC50: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .
loading...
    loading...
Cat. No.: HY-147409
CAS No.: 2075750-05-7
Target:  

CDK

Research Areas:  

Cancer

Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .
loading...
    loading...
Cat. No.: HY-16559A
CAS No.: 920113-02-6
Synonyms: P276-00 free base
Target:  

CDK

Research Areas:  

Cancer

Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
Cat. No.: HY-111932
CAS No.: 244021-67-8
Target:  

CDK GSK-3

Research Areas:  

Cancer

Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .
loading...
    loading...
Cat. No.: HY-10424R
CAS No.: 802539-81-7
Synonyms: PHA-848125 (Standard)
Research Areas:  

Cancer

Milciclib (Standard) is the analytical standard of Milciclib. This product is intended for research and analytical applications. Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
loading...
    loading...
Cat. No.: HY-18981R
CAS No.: 5928-25-6
Synonyms: (+)-Decursin (Standard)
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].
loading...
    loading...
Cat. No.: HY-18981S
Synonyms: (+)-Decursin-d6
Decursin-d6 ((+)-Decursin-d6) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .
loading...
    loading...
Cat. No.: HY-187643
CAS No.: 304911-07-7
CGC-11144 hydrochloride is a polyamine analog. CGC-11144 hydrochloride reduces the kinase activities of CDK4, CDK2 and CDK6, induces activation of the p53 pathway and p53-dependent p21 expression, and mediates cell cycle regulation, growth inhibition and apoptosis. CGC-11144 hydrochloride induces G1 phase cell cycle arrest, downregulates cyclin D1 and cyclin B1, upregulates cyclin E, induces dephosphorylation of pRb, and inhibits ERα-mediated transcriptional activity by disrupting the DNA binding of Sp1/Sp3 to the ERα promoter, while also stimulating activation of the JNK/AP-1 pathway. CGC-11144 hydrochloride can be used in research related to breast cancer, choroidal neovascularization and cancer .
loading...
    loading...
  • 1